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Introduction {#sec1}
============

Bone marrow stromal cells (BMSCs) are multipotent progenitor cells that form osteoblasts and adipocytes *in vivo*, and have trilineage potential to form osteoblasts, adipocytes, and chondrocytes *in vitro*. Originally identified as cells forming fibroblast-like colonies (fibroblastic colony-forming units \[CFU-F\]), recent studies have identified multiple markers to prospectively identify BMSCs, including CD146 in human tissues ([@bib42]), platelet-derived growth factor receptor (PDGFR) ([@bib33]), *Cxcl12* ([@bib13], [@bib16], [@bib39], [@bib46]), *Scf* ([@bib14]), *Nestin-GFP* ([@bib22], [@bib29]), *Mx1-Cre* ([@bib40]), *Leptin receptor* (*Lepr*)*-Cre* ([@bib14], [@bib38], [@bib55]), and *Prx1-Cre* ([@bib16], [@bib55]) in mice. These markers identify a largely overlapping population of BMSCs. For instance, stromal populations that express high levels of *Cxcl12* (Cxcl12-abundant reticular \[CAR\] cells) ([@bib46]) largely overlap with cells that can be identified by *Prx1-Cre* labeling ([@bib16]), *Lepr-Cre* labeling ([@bib14]), and *Nestin-GFP* expression ([@bib55]). Genetic manipulations with these tools are beginning to reveal important insights into the role of bone marrow BMSCs in bone maintenance and hematopoiesis.

BMSCs are a component of the perivascular HSC niche along with endothelial cells, and express high levels of HSC growth factors ([@bib20], [@bib34]). HSCs identified by highly selective markers were found in close proximity to endothelial cells and the surrounding BMSCs ([@bib1], [@bib9], [@bib21], [@bib29], [@bib46]). Depletion of BMSCs in *Cxcl12-diphtheria toxin receptor* (DTR) or in *Nestin-Cre*;*inducible-DTR* mice reduced the numbers of HSCs in the bone marrow, affirming the importance of BMSCs in HSC maintenance ([@bib29], [@bib39]). Moreover, deletion of HSC growth factors produced by BMSCs, such as stem cell factor (SCF) or CXCL12, depleted bone marrow HSCs, establishing that BMSCs support HSCs by providing these growth factors ([@bib14], [@bib13], [@bib16]). In addition to producing HSC growth factors, the immature state of BMSCs is also important for HSC maintenance. Accumulation of marrow adipocyte is a hallmark of aging ([@bib26]), and this age-related expansion of adipocytes negatively affects HSCs ([@bib3]). Murine caudal vertebrae is enriched in adipocytes, making this location refractory for HSC expansion ([@bib35]). Consistently, BMSC-specific deletion of *Foxc1*, a transcription factor highly expressed in BMSCs, results in the accumulation of adipocytes in the marrow and severely impairs hematopoiesis and HSC maintenance ([@bib38]). On the other hand, stromal components committed to the adipocytic fate as defined by adiponectin expression play a positive role in hematopoietic recovery after myeloablation by producing SCF, possibly as an adaptive response to the damage ([@bib54]). Thus, not only the growth factor secretome but also the differentiation status of BMSCs is intimately linked to HSC maintenance. However, little is known regarding the mechanisms that regulate fate determination of BMSCs.

The polycomb group protein BMI1 is an epigenetic regulator involved in development and cell-fate determination ([@bib44]). BMI1 is a component of the polycomb repressive complex 1 (PRC1) that catalyzes the repressive histone modification H2A ubiquitination (H2Aubi) ([@bib11], [@bib50]). The PRC1 was previously considered to depend on another polycomb complex, the PRC2, which catalyzes repressive histone H3 lysine 27 trimethylation (H3K27me3) to associate with chromatin ([@bib51]). However, recent studies have revealed a more complex interplay between PRC1 and PRC2, whereby PRC1-catalyzed H2Aubi recruits and stabilizes PRC2 association with chromatin ([@bib6], [@bib44]). PRC1 and PRC2 govern developmental programs in pluripotent and tissue stem cells, as exemplified by the finding that H2Aubi and H3K27me3 decorates chromatin of gene loci that encodes developmental genes, preventing precocious expression of these genes in stem cells ([@bib4], [@bib5], [@bib8], [@bib24]). Consistently, *Bmi1-*deficient mice exhibit multiple developmental defects including skeletal transformation, neuronal and hematopoietic defects, growth retardation, and postnatal lethality ([@bib2], [@bib25], [@bib32], [@bib41], [@bib48]). *Bmi1* regulates self-renewal of HSCs both cell intrinsically in HSCs and cell extrinsically through its maintenance of the microenvironment ([@bib37], [@bib41]). Since *Bmi1*-deficient mice exhibit myriad developmental defects in many organs, it remains unclear in which cell type *Bmi1* functions to support HSCs cell extrinsically, in addition to its cell-intrinsic role in HSC self-renewal.

Here we show that *Bmi1* is required in BMSCs to maintain HSCs, by suppressing the adipogenic differentiation of BMSCs. We found that BMSCs expressed high levels of *Bmi1*, and its expression level was downregulated upon adipocytic differentiation and during aging. Conditional deletion of *Bmi1* from BMSCs increased the numbers of adipocytes in the bone marrow, depleting HSCs and hematopoietic cells. *Bmi1* was required to epigenetically repress multiple developmental programs in BMSCs, including a novel adipogenic differentiation program mediated by Pax3. Our findings establish that *Bmi1* maintains the HSC niche by suppressing adipogenesis of BMSCs.

Results {#sec2}
=======

*Bmi1* Is Expressed in Immature Bone Marrow BMSCs and Suppresses Senescence {#sec2.1}
---------------------------------------------------------------------------

To begin to study how *Bmi1* in bone marrow stroma cells regulates HSCs cell extrinsically, we determined *Bmi1* expression levels in BMSCs (CD140^+^CD45^−^Ter119^−^), non-BMSC stroma cells (CD140^−^CD45^−^Ter119^−^), and hematopoietic cells (CD45/Ter119^+^) by quantitative PCR (qPCR). CD140^+^CD45^−^Ter119^−^ BMSCs expressed high levels of HSC niche factors *Kitl* (encoding SCF) and *Cxcl12* ([@bib14], [@bib13], [@bib16]), BMSC markers *Lepr* and *Pdgfra* ([@bib14], [@bib33]), and transcription factors *Foxc1* and *Grem1* ([@bib38], [@bib52]) ([Figures 1](#fig1){ref-type="fig"}A and 1B). As shown in [Figure 1](#fig1){ref-type="fig"}C, *Bmi1* mRNA was also highly expressed in BMSCs compared with non-BMSC stroma cells and hematopoietic cells. To examine whether expression of *Bmi1* in BMSCs changes upon lineage commitment, we isolated BMSCs from wild-type bone marrow and cultured them with or without differentiation stimuli for adipocytes or osteoblasts, and measured *Bmi1* expression levels by qPCR. *Bmi1* expression was increased upon osteogenic stimuli, while it was decreased in cells that were induced to undergo adipocytic differentiation ([Figure 1](#fig1){ref-type="fig"}D). These results suggest that *Bmi1* is highly expressed in undifferentiated BMSCs and that reduction in *Bmi1* expression accompanies commitment to the adipocytic fate.Figure 1*Bmi1* Is Highly Expressed in BMSCs and Suppresses Senescence(A) Schematic showing the gating strategy to isolate BMSCs (CD140a^+^CD45^−^Ter119^−^), non-BMSC stroma cells (CD140a^−^CD45^−^Ter119^−^), and hematopoietic cells (CD45^+^/Ter119^+^).(B and C) qPCR showing the expression of HSC niche factors and regulators (B) and *Bmi1* (C) in BMSCs, other stroma cells, and hematopoietic cells (Hem) (n = 3).(D) *Bmi1* expression 3 weeks after osteogenic stimulation (left) and adipocytic induction (right) (n = 7--9).(E) qPCR of *Bmi1* expression in purified BMSCs and HSCs from *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 3--4).(F) The frequencies (left) and total numbers (right) of BMSCs in *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 6).(G) The numbers of CFU-F per 1 × 10^6^ bone marrow cells following *Bmi1* deletion (n = 6).(H) Passaging of *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs (n = 5).(I and J) The frequencies of SAβ-gal^+^ cells (n = 5) (I) and expression of *Ink4a* as determined by qPCR in *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs (normalized to 18S rRNA) (J) (n = 3).In (B--E), expression values were normalized to β-actin. All data represent mean ± standard deviation (SD). ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test. ns, not significant. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To study the role of *Bmi1* in BMSC function, we conditionally deleted *Bmi1* using *Prx1-Cre*. *Prx1-Cre* has been shown to be expressed in CAR cells ([@bib46]), *Lepr*^+^ stroma cells ([@bib13], [@bib16]), *Scf*-expressing HSC niche cells ([@bib14]), and *Nestin*^+^ BMSCs ([@bib29]). *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice were born normally and did not exhibit any changes in body weight, fat mass, or lean mass, although the amount of circulating adiponectin was lower than those in *Bmi1*^*fl/fl*^ mice (referred to as control) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). qPCR to detect *Bmi1* in purified BMSCs from control *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice showed that *Bmi1* expression was significantly depleted in the BMSCs from *Prx1-Cre;Bmi1*^*fl/fl*^ mice, confirming efficient deletion of *Bmi1* ([Figure 1](#fig1){ref-type="fig"}E). In young adult mice of 2--4 months of age, we did not detect any differences in the frequencies or total numbers of BMSCs in the long bones between *Bmi1*^*fl/fl*^ and *Prx1-Cre;Bmi1*^*fl/fl*^ mice ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}B). Consistently, enumeration of BMSCs in a CFU-F assay showed that the numbers of CFU-F were not significantly affected by *Bmi1* deletion ([Figure 1](#fig1){ref-type="fig"}G). We then serially passaged BMSCs *in vitro* to examine the proliferative capacity of *Bmi1*-deficient BMSCs. Whereas wild-type BMSCs expanded significantly over three passages, *Bmi1*-deficient BMSCs ceased proliferation upon passage 2 and failed to expand in later passages ([Figure 1](#fig1){ref-type="fig"}H). Since *Bmi1* suppresses senescence by silencing the *Ink4a/Arf* locus ([@bib19]), we examined whether *Bmi1*-deficient BMSCs undergo senescence. *Bmi1*-deficient BMSC cultures exhibited significantly more senescent-associated β-gal (SAβ-gal)^+^ cells and had increased expression of *Ink4a*, a marker of senescent cells ([Figures 1](#fig1){ref-type="fig"}I--1J and [S1](#mmc1){ref-type="supplementary-material"}C). These results establish that *Bmi1* is highly expressed in BMSCs and suppresses senescence *in vitro*.

*Bmi1* Suppresses Adipogenic Differentiation of BMSCs {#sec2.2}
-----------------------------------------------------

The finding that *Bmi1* expression is reduced in BMSCs upon commitment to the adipocytic fate prompted us to test whether *Bmi1* deletion promotes adipocyte differentiation of BMSCs. We cultured BMSCs from *Prx1-Cre;Bmi1*^*fl/fl*^ and control *Bmi1*^*fl/fl*^ mice and stimulated BMSCs to undergo adipocytic, osteoblastic, or chondrocytic differentiation *in vitro*. While wild-type BMSCs underwent osteoblastic differentiation after 2 weeks of induction, osteoblastic differentiation of *Prx1-Cre;Bmi1*^*fl/fl*^ BMSCs was delayed, and fewer alizarin red-positive osteoblasts were observed after 4 and 6 weeks of induction ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). Chondrogenesis occurred in *Bmi1*-deficient BMSCs similar to wild-type BMSCs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). In contrast, the accelerated adipocytic differentiation of *Prx1-Cre;Bmi1*^*fl/fl*^ BMSCs compared with wild-type BMSCs was observed after only 1 week of induction ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}C). These changes in differentiation potential were confirmed by gene expression changes. Consistent with the accelerated adipocytic differentiation of *Bmi1*-deficient BMSCs, genes involved in adipogenesis such as *Pparg*, *Fabp4*, and *Adipoq* were increased in *Bmi1*-deficient BMSCs 3 weeks after induction compared with control BMSCs ([Figure 2](#fig2){ref-type="fig"}C). Conversely, genes involved in osteogenesis such as *Sp7* (Osterix) and *Runx2* were reduced in *Bmi1*-deficient BMSCs upon osteoblastic differentiation compared with control BMSCs ([Figure 2](#fig2){ref-type="fig"}D). *In vitro* bromodeoxyuridine (BrdU) incorporation assays revealed that *Bmi1* deletion does not affect proliferation of BMSCs or adipocyte progenitors ([Figure S2](#mmc1){ref-type="supplementary-material"}D). These results suggest that *Bmi1* deletion primes BMSCs to undergo adipocytic differentiation.Figure 2*Bmi1* Deletion from BMSCs Increased Adipogenesis *In Vitro*(A and B) Representative images showing reduced osteogenesis (A) and increased adipogenesis (B) in *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs upon *in vitro* induction (n = 3).(C) Expression of adipogenic genes (*Pparg*, *Fabp4*, and *Adipoq*, normalized to 18S rRNA) in *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs (n = 5--7) 3 weeks after induction (n = 5), as determined by qPCR.(D) Osteogenic gene (*Osterix* and *Runx2*, normalized to 18S rRNA) expression in *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs (n = 3).All data represent mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We then determined whether *Bmi1* deletion from BMSCs affects the bone marrow environment by regulating osteogenesis or adipogenesis *in vivo*. We first performed microcomputed tomography (μCT) scanning of intact femurs from young adult mice to examine the bone parameters. *Bmi1* deletion from BMSCs did not affect the thicknesses, densities, or the bone volume to total volume ratios of cortical and trabecular bones or the numbers of trabecular bones ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S3](#mmc1){ref-type="supplementary-material"}A--S3G), suggesting that *Bmi1* is largely dispensable for bone formation and maintenance. Since *Bmi1* expression was attenuated upon adipogenic stimuli ([Figure 1](#fig1){ref-type="fig"}D), we tested whether *Bmi1* deletion affects adipogenesis in the bone marrow. To quantitatively analyze the adipocyte volume in the marrow, we performed μCT scanning of osmium tetroxide-stained femurs ([Figures 3](#fig3){ref-type="fig"}C and 3D). Two- to 6-month-old wild-type mice exhibited some adipocytes in the epiphyses, whereas adipocytes expanded significantly in the epiphyses and extended to the diaphyses of femurs in *Prx1-Cre;Bmi1*^*fl/fl*^ mice ([Figures 3](#fig3){ref-type="fig"}C, 3D, and [S3](#mmc1){ref-type="supplementary-material"}H). Cross-sections of the femurs stained with osmium tetroxide confirmed this finding ([Figure 3](#fig3){ref-type="fig"}E). In contrast to the expansion of adipocytes in the long bones, we did not detect significant changes in adipocyte volume in the lumbar vertebrae ([Figure S3](#mmc1){ref-type="supplementary-material"}I), consistent with the selective expression of *Prx1-Cre* in the limbs ([@bib27]). These results establish that *Bmi1* is required to suppress accumulation of bone marrow adipocytes.Figure 3*Bmi1* Deletion from BMSCs Increased Adipogenesis *In Vivo*(A and B) μCT analyses of the cortical and trabecular bone thickness (A) and bone volume/total volume ratio (BV/TV) (B) (n = 6).(C) Representative μCT image of femurs stained with osmium tetroxide.(D) Quantification of the adipocyte volume to total volume ratio in 2-month-old *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 3).(E) Representative images of femur sections stained with osmium tetroxide (n = 4).(F) *Bmi1* expression (normalized to 18S rRNA) in BMSCs isolated from aged mice (18--24 months old, n = 4) compared with those isolated from young mice (2--4 months old, n = 5). Mice of both sexes were analyzed, with representative images from female mice shown.All data represent mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test. ns, not significant. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Accumulation of marrow adipocytes is a hallmark of aging ([@bib26]). The finding that the bone marrow of young adult *Prx1-Cre;Bmi1*^*fl/fl*^ mice become filled with adipocytes prompted us to examine *Bmi1* expression in BMSCs isolated from mice with different ages. CD140^+^CD45^−^Ter119^−^ BMSCs were isolated from 3- to 5-month-old and 18- to 24-month-old wild-type mice and *Bmi1* expression was quantified by qPCR. We found that older mice had lower *Bmi1* expression in BMSCs compared with young mice ([Figure 3](#fig3){ref-type="fig"}F). These results illustrate the links between aging, adipocyte expansion, and loss of *Bmi1* expression; aging is accompanied by the expansion of marrow adipocytes and loss of *Bmi1* expression in BMSCs, while *Bmi1* deletion from BMSCs causes precocious accumulation of marrow adipocytes.

Deletion of *Bmi1* from BMSCs Reduces HSCs and Attenuates Hematopoiesis {#sec2.3}
-----------------------------------------------------------------------

To determine the effect of *Bmi1* deletion on the hematopoietic microenvironment, we analyzed hematopoiesis in the bone marrow of *Prx1-Cre;Bmi1*^*fl/fl*^ mice. At 2 months of age, we observed a slight reduction in bone marrow cellularity, possibly due to the expansion of bone marrow adipocytes following *Bmi1* deletion. In contrast to this minor reduction at early time points, a more severe phenotype was observed at 6 months of age ([Figures 4](#fig4){ref-type="fig"}A--4H and [S4](#mmc1){ref-type="supplementary-material"}A--S4D). Bone marrow cellularity significantly increased in *Bmi1*^*fl/fl*^ mice from 2 to 6 months of age, but this increase was not observed in *Prx1-Cre;Bmi1*^*fl/fl*^ mice, which had significantly reduced bone marrow cellularity at 6 months compared with age-matched control mice ([Figure 4](#fig4){ref-type="fig"}A). Hematopoietic progenitor cells also expanded from 2 to 6 months of age in *Bmi1*^*fl/fl*^ mice but not in *Prx1-Cre;Bmi1*^*fl/fl*^ mice. Overall, *Bmi1* deletion resulted in significant depletion of HSCs, common lymphoid progenitors (CLPs), common myeloid progenitors (CMPs), and granulocyte macrophage progenitors (GMPs) ([Figures 4](#fig4){ref-type="fig"}B--4H and [S4](#mmc1){ref-type="supplementary-material"}A--S4D). Fractionating HSCs into long- and short-term (LT and ST) HSCs using CD34 and FLT3 revealed similar depletion of HSCs ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}C). As expected, *Prx1-Cre* did not affect the expression of *Bmi1* in HSCs ([Figure 1](#fig1){ref-type="fig"}E). Multipotent progenitors (MPPs) and megakaryocyte erythroid progenitors (MEPs) also showed trends toward becoming depleted following *Bmi1* deletion ([Figures 4](#fig4){ref-type="fig"}D and 4G). Total numbers of hematopoietic colony-forming cells in hind limbs were significantly reduced in 6-month-old *Prx1-Cre;Bmi1*^*fl/fl*^ mice ([Figure 4](#fig4){ref-type="fig"}I). Consistent with the depletion of hematopoietic progenitor cells, *Prx1-Cre;Bmi1*^*fl/fl*^ mice had reduced white blood cells counts compared with *Bmi1*^*fl/fl*^ mice ([Figures 4](#fig4){ref-type="fig"}J--4M). Despite the significant reduction in bone marrow hematopoiesis, we did not observe extramedullary hematopoiesis in *Prx1-Cre;Bmi1*^*fl/fl*^ mice. The numbers of HSCs and other progenitors in the spleen and the liver were not different between *Bmi1*^*fl/fl*^ and *Prx1-Cre;Bmi1*^*fl/fl*^ mice ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F). CFU assays to detect hematopoietic progenitor activity in the spleen and the liver also failed to detect any differences between *Bmi1*^*fl/fl*^ and *Prx1-Cre;Bmi1*^*fl/fl*^ mice ([Figure 4](#fig4){ref-type="fig"}N). These results establish that deleting *Bmi1* from BMSCs reduces the number of HSCs and other hematopoietic stem and progenitor cells (HSPCs) in the bone marrow, thereby impairing hematopoiesis in adult mice.Figure 4Deletion of *Bmi1* from BMSCs Impairs Steady-State Hematopoiesis(A) Bone marrow (BM) cellularity in 2- and 6-month-old *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 3--4).(B--H) Absolute numbers of CD150^+^CD48^−^lineage^−^Sca-1^+^c-kit^+^ HSCs (B), LT-HSCs (CD34^−^Flt3^−^lineage^−^Sca-1^+^c-kit^+^ cells), and ST-HSCs (CD34^+^Flt3^−^lineage^−^Sca-1^+^c-kit^+^ cells) (C), MPPs (D), CMPs (E), GMPs (F), MEPs (G), and CLPs (H) in *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice at 2 and 6 months (n = 4). Data in (C) are from 6-month-old mice.(I--M) Total numbers of hematopoietic colonies (CFU-C) formed from bone marrow cells of hind limbs (n = 3) (I). White blood cell (WBC) (J), red blood cell (RBC) (K), and platelet (PLT) (L) counts, and lineage distribution (M) in the peripheral blood (PB) of *Bmi1*^*fl/fl*^ (Ctrl) and *Prx1-Cre*;*Bmi1*^*fl/fl*^ (KO) mice at 2 and 6 months (n = 4).(N) Numbers of hematopoietic colonies formed per 200,000 cells isolated from the spleen and liver (n = 3). Mice of both sexes were used.All data represent mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test. ns, not significant. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Previous reports have shown that adipocytes in the tail vertebrae promote quiescence and regenerative potential but reduce the numbers of HSCs ([@bib35]). The expansion of adipocytes in *Prx1-Cre;Bmi1*^*fl/fl*^ mice prompted us to examine the cell-cycle activity of HSCs in these mice by BrdU incorporation assays. *Prx1-Cre;Bmi1*^*fl/fl*^ and control *Bmi1*^*fl/fl*^ mice were treated with BrdU for 7 days and BrdU incorporation into HSCs was analyzed by flow cytometry. Interestingly, we found that BrdU incorporation specifically into HSCs was significantly reduced, whereas BrdU incorporation into other immature cells such as MPPs, HPC1, and HPC2 ([@bib36]) was not affected by deleting *Bmi1* from BMSCs ([Figures 5](#fig5){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}G). Importantly, deletion of *Bmi1* from hematopoietic cells using *Vav-Cre* did not affect division of HSCs ([Figure 5](#fig5){ref-type="fig"}B), indicating that *Bmi1* is required in the hematopoietic microenvironment, and not in HSCs themselves, to maintain HSC division. HSCs in *Prx1-Cre;Bmi1*^*fl/fl*^ mice were capable of entering the cell cycle, since treating mice with cyclophosphamide and granulocyte-colony stimulating factor increased BrdU^+^ HSCs in *Prx1-Cre;Bmi1*^*fl/fl*^ mice comparable with *Bmi1*^*fl/fl*^ mice ([Figure S4](#mmc1){ref-type="supplementary-material"}H). To examine the function of the residual HSCs, we isolated 50 HSCs from *Prx1-Cre;Bmi1*^*fl/fl*^ and control *Bmi1*^*fl/fl*^ mice and performed a competitive HSC transplantation assay. We found that HSCs from *Prx1-Cre;Bmi1*^*fl/fl*^ mice do not exhibit any defects in long-term multilineage reconstitution compared with control HSCs ([Figure 5](#fig5){ref-type="fig"}C). We did not observe any differences in the lineage contribution of HSCs isolated from *Prx1-Cre;Bmi1*^*fl/fl*^ or control *Bmi1*^*fl/fl*^ mice ([Figure 5](#fig5){ref-type="fig"}D). Thus, deletion of *Bmi1* from BMSCs causes quiescence and depletion of HSCs and reduces the numbers of many hematopoietic progenitor populations downstream of HSCs.Figure 5Deletion of *Bmi1* from BMSCs Causes Quiescence of HSCs(A) Incorporation of BrdU during a 7-day pulse into HSC, MPP, HPC1, and HPC2 of *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 3).(B) BrdU incorporation into HSCs, MPPs, HPC1, and HPC2 in *Bmi1*^*fl/fl*^ and *Vav1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 3).(C and D) Long-term reconstitution assays with 50 HSCs isolated from *Bmi1*^*fl/fl*^ or *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 3) (C). Lineage contribution from transplanted HSCs at 16 weeks after transplantation (n = 3) (D).All data represent mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test.

*Bmi1* Deletion Derepresses Developmental Programs in BMSCs {#sec2.4}
-----------------------------------------------------------

Since PRC1 is known to repress developmental gene expression in embryonic stem cells and tissue stem cells, we next analyzed the gene expression profiles of *Bmi1*^*fl/fl*^ and *Prx1-Cre;Bmi1*^*fl/fl*^ BMSCs. Freshly isolated BMSCs from *Bmi1*^*fl/fl*^ and *Prx1-Cre;Bmi1*^*fl/fl*^ mice were subjected to RNA sequencing (RNA-seq). Compared with whole bone marrow cells, many genes known to be expressed in BMSCs were highly enriched in our gene expression profiles, including *Kitl*, *Cxcl12*, *Lepr*, *Pdgfra*, *Foxc1*, and *Grem1* ([Figure 6](#fig6){ref-type="fig"}A), attesting to the purity of the BMSCs we used for RNA-seq.Figure 6*Bmi1* Deletion Derepresses Developmental Programs in BMSCs(A) Differentially expressed genes in BMSCs compared with whole bone marrow cells (n = 3).(B and C) GSEA (B) and GO analysis (C) of *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs compared with *Bmi1*^*fl/fl*^ BMSCs (n = 3). NES, normalized enrichment score; FDR, false discovery rate.(D) Differentially expressed genes in *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs compared with *Bmi1*^*fl/fl*^ BMSCs (n = 3).(E and F) Pairwise GSEAs testing the enrichment of genes upregulated (E) or downregulated (F) in *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs in CD45^−^CD31^−^Sca-1^+^CD24^+^ stem cell-like cells (MSCs), CD45^−^CD31^−^Sca-1^−^PDGFRα^+^ osteochondrogenic progenitor cells (OPCs), CD45^−^CD31^−^Sca-1^+^CD24^−^ adipogenic progenitor cells (APCs), and CD45^−^CD31^−^Sca-1^−^ZFP423^+^ pre-adipocytes (PreAd). Left panels show the degree of enrichment in a pairwise comparison. Right panels show the cumulative enrichment scores (ES) representing the sum of enrichment scores for each cell type when compared across all other cell types (n = 3).Data in (A) and (D) represent log~2~ fold change ± log~2~(standard error) and other data represent mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test.

To broadly examine the gene expression changes that occur in BMSCs after *Bmi1* deletion, we performed a gene set enrichment analysis (GSEA) between wild-type and *Bmi1*-deficient BMSCs using the MSigDB collection of gene sets. Consistent with the role of BMI1 in the PRC1 complex, we found positive enrichment of gene sets that represent PRC2 target genes and genes with histone H3K27me3 modification in *Bmi1*-deficient BMSCs ([Figure 6](#fig6){ref-type="fig"}B and [Table S1](#mmc2){ref-type="supplementary-material"}), indicating that polycomb target genes with H3K27me3 are being derepressed in the absence of *Bmi1*. Since the PRCs are involved in developmental programs in pluripotent stem cells, we assessed whether *Bmi1* regulates developmental genes in BMSCs. GSEA revealed that gene ontology (GO) terms related to developmental processes, such as organ morphogenesis, pattern specification, and anterior/posterior patterning, were all enriched in *Bmi1*-deficient BMSCs ([Figure 6](#fig6){ref-type="fig"}C). We also identified gene sets representing fat cell differentiation and adiponectin-activated pathways as enriched in *Bmi1*-deficient BMSCs. Consistent with the dysregulation of developmental processes after deleting *Bmi1*, several transcription regulators involved in developmental processes, including posterior *Hox* genes (*Hoxc10*-*Hoxc13*), several Paired box transcription factors (*Pax3* and *Pax9*), *Engrailed 2* (*En2*), *Gli1*, and *Sall1* were derepressed in *Bmi1*-deficient BMSCs ([Figure 6](#fig6){ref-type="fig"}D). These results suggest that *Bmi1* is required to suppress developmental gene programs in BMSCs, possibly through its role in the PRC1 complex and in collaboration with the PRC2.

To determine whether *Bmi1*-deficient BMSCs exhibit transcriptional changes indicative of precocious adipogenic differentiation, we compared the expression profiles of *Bmi1*-deficient BMSCs with those from a recent study that identified four fractions of bone marrow stroma cells with osteogenic and/or adipogenic potential;CD45^−^CD31^−^Sca-1^+^CD24^+^ stem cell-like cells (MSCs), CD45^−^CD31^−^Sca-1^−^PDGFRα^+^ osteochondrogenic progenitor cells (OPCs), CD45^−^CD31^−^Sca-1^+^CD24^−^ adipogenic progenitor cells, and CD45^−^CD31^−^Sca-1^−^ZFP423^+^ pre-adipocytes (PreAd) ([@bib3]). We created gene sets that are upregulated or downregulated in *Bmi1*-deficient BMSCs. We then compared MSCs, OPCs, APCs, and PreAd in a pairwise GSEA ([@bib45], [@bib49]) and determined the enrichment scores of each population in regard to our custom gene sets. These analyses revealed that pre-adipocytes are enriched in genes upregulated in *Bmi1*-deficient BMSCs ([Figure 6](#fig6){ref-type="fig"}E), whereas osteochondrogenic progenitor cells were enriched in genes downregulated in *Bmi1*-deficient BMSCs ([Figure 6](#fig6){ref-type="fig"}F). These results suggest that *Bmi1*-deficient BMSCs share gene expression similarity with pre-adipocytes, consistent with the accelerated adipogenic and delayed osteogenic differentiation of these cells. Together, these results indicate that *Bmi1* deletion initiates a precocious adipocytic differentiation program in BMSCs.

We then examined the role of *Bmi1* in maintaining the epigenome of BMSCs. BMSCs were isolated from *Bmi1*^*fl/fl*^ and *Prx1-Cre;Bmi1*^*fl/fl*^ mice and chromatin immunoprecipitation sequencing (ChIP-seq) performed with antibodies against the PRC1 mark H2Aubi and PRC2 mark H3K27me3. The *Hoxc10*-*Hoxc13* cluster, particularly on the centromere-proximal side with the *Hoxc13* gene, was covered by the repressive H2Aubi and H3K27me3 modification in wild-type BMSCs ([Figure 7](#fig7){ref-type="fig"}A). In *Bmi1*-deficient BMSCs, the H2Aubi modification was reduced in this region, consistent with the notion that the Bmi1-containing PRC1 catalyzes H2A ubiquitylation ([@bib11], [@bib50]) ([Figure 7](#fig7){ref-type="fig"}A). Interestingly, H3K27me3 catalyzed by PRC2 was also reduced in this region in *Bmi1*-deficient BMSCs, suggesting that the BMI1-containing PRC1 is required to maintain the PRC2-catalyzed H3K27me3 modification on chromatin. Furthermore, we found that the *Cdkn2a* locus, which encodes the *Ink4a/Arf* tumor-suppressor genes that are known to be repressed by PRC1, was covered by H2Aubi and H3K27me2 in a *Bmi1*-dependent manner, consistent with the derepression of *Ink4a* and *Arf* ([Figure 7](#fig7){ref-type="fig"}B). Interestingly, among the genes that encode transcription factors involved in developmental processes, we found significant changes in both H2Aubi and H3K27me3 in the promoter region of *Pax3* in *Bmi1*-deficient BMSCs compared with controls ([Figure 7](#fig7){ref-type="fig"}C). *Bmi1* deletion decreased enrichment of H2Aubi and H3K27me3 in the *Pax3* promoter region. Together with the finding that *Pax3* expression is derepressed in the absence of *Bmi1* ([Figure 6](#fig6){ref-type="fig"}D), this finding raised the possibility that *Pax3* is a direct target of BMI1 in BMSCs.Figure 7Derepressed *Pax3* in the Absence of *Bmi1* Promotes Adipogenic Differentiation of BMSCs(A--C) Genomic snapshot at the *Hoxc* gene locus (A), *Ink4a/Arf* locus (B), and *Pax3* locus (C) showing ChIP-seq profiles of H2Aubi and H3K27me3 in *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ BMSCs (n = 3).(D--F) Knockdown efficiency (D), changes in adipogenesis (E), and changes in osteogenesis (F) upon knockdown of *Pax3* in *Bmi1*^*fl/fl*^ and *Prx1-Cre*;*Bmi1*^*fl/fl*^ mice (n = 3).All data represent mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by two-way ANOVA with Bonferroni post hoc tests. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Derepressed *Pax3* in the Absence of *Bmi1* Promotes Adipogenic Differentiation of BMSCs {#sec2.5}
----------------------------------------------------------------------------------------

PAX3 is a transcriptional regulator that integrates cell extrinsic signals to cell-fate determination, regulating multiple tissue stem/progenitor cells including neural crest stem cells, muscle satellite cells, and melanoblasts ([@bib7], [@bib23], [@bib53]). *Pax3* was highly expressed in BMSCs compared with hematopoietic cells and non-BMSCs and its expression level did not change with age ([Figure S5](#mmc1){ref-type="supplementary-material"}A). To determine the role of *Pax3* in BMSCs, we knocked down *Pax3* expression using short hairpin RNA (shRNA) and tested whether the derepressed *Pax3* regulates adipogenesis in the absence of *Bmi1*. As controls, we also knocked down the expression of *Pparg*, a master regulator of fat cell fate, and *Ink4a/Arf*, a prototypical target of the PRC1/2 in *Bmi1*^*fl/fl*^ and *Prx1-Cre;Bmi1*^*fl/fl*^ mice. CD140^+^CD45^−^Ter119^−^ BMSCs were isolated from *Prx1-Cre;Bmi1*^*fl/fl*^ and control mice and infected with lentiviral shRNA constructs and stimulated to undergo adipogenic or osteoblastic differentiation. shRNA for these genes effectively knocked down the expression of *Pax3*, *Pparg*, and *Ink4a/Arf* in *Bmi1*-deficient BMSCs ([Figures 7](#fig7){ref-type="fig"}D, [S5](#mmc1){ref-type="supplementary-material"}B, and S5C). *Ink4a/Arf* knockdown increased adipogenesis in both wild-type and *Bmi1*-deficient BMSCs ([Figure S5](#mmc1){ref-type="supplementary-material"}D), suggesting that the derepressed *Ink4a/Arf* in *Bmi1*-deficient BMSCs counteracts rather than promotes adipogenesis. As expected, *Pparg* knockdown significantly attenuated the adipogenesis in both wild-type and *Bmi1*-deficient BMSCs ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Importantly, *Pax3* knockdown also significantly blunted the increased adipogenesis observed in *Bmi1*-deficient BMSCs ([Figures 7](#fig7){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}F), indicating that the derepressed *Pax3* expression in *Bmi1*-deficient BMSCs is at least partly responsible for the enhanced adipogenesis. *Pax3* knockdown also increased osteogenesis in both wild-type and *Bmi1*-deficient BMSCs ([Figures 5](#fig5){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}G). Together, these results indicate that *Pax3*, which is repressed by BMI1 in immature BMSCs, promotes adipogenesis and suppresses osteogenesis in bone marrow BMSCs.

Discussion {#sec3}
==========

Recent studies have established the role of bone marrow BMSCs as a crucial component of the HSC niche, responsible for the production of multiple secreted or membrane-bound factors to support HSCs, and elucidated their contribution toward osteogenic and adipogenic cells in the marrow ([@bib14], [@bib13], [@bib16], [@bib18], [@bib39], [@bib40], [@bib46], [@bib52], [@bib55]). However, relatively little is known of how the cell fate of BMSCs is regulated and the consequences of dysregulated BMSC cell fate on HSC maintenance. Here we show that *Bmi1* is required in BMSCs to suppress adipogenic differentiation and thus maintain adult bone marrow HSCs. We found that *Bmi1* is required for the repression of *Pax3*, which we identified as a novel adipogenic regulator of BMSCs.

Several studies have shown that *Bmi1* expression is downregulated during aging in several tissues ([@bib10], [@bib12], [@bib47]). Consistent with these reports, we found that *Bmi1* expression is reduced in BMSCs isolated from older mice. Furthermore, we found that *Bmi1* expression was reduced upon exposing wild-type BMSCs to adipogenic stimuli, suggesting that reduced *Bmi1* expression facilitates adipogenic differentiation. These studies corroborate the expansion of adipocytes in the marrow with age, known as the age-related conversion of red to yellow marrow ([@bib26]). As lineage-tracing studies indicate that bone marrow BMSCs are the major source of marrow adipocytes ([@bib3], [@bib55]), our results are consistent with the model that *Bmi1* expression is attenuated in bone marrow BMSCs with age, causing promiscuous differentiation of BMSCs to adipocytes.

Expansion of adipocytes after deleting *Bmi1* from BMSCs impaired HSC niche function, reducing proliferation and the number of HSCs, suggesting that *Bmi1*-deficient BMSCs or increased adipocytes create a quiescent HSC niche. Prior studies have also demonstrated that adipocytes negatively regulate the numbers of murine HSCs ([@bib3], [@bib35]). The maintenance of human HSCs *in vitro* is also improved by co-culturing them with bone marrow adipocytes ([@bib28]). Interestingly, although the numbers of HSCs were depleted in *Prx1-Cre;Bmi1*^*fl/fl*^ mice, residual HSCs were as functional as HSCs from control mice. As a consequence of HSC depletion, multiple downstream progenitor cells were also depleted and *Prx1-Cre;Bmi1*^*fl/fl*^ mice had lower white blood cell counts compared with wild-type mice. The effects of *Bmi1* deletion on peripheral blood cells were modest compared with the effects on bone marrow HSPCs, consistent with a study demonstrating that homeostatic blood production can be sustained with few HSPCs ([@bib43]). The reduction in lymphocytes in the peripheral blood is consistent with aging; however, many changes that accompany HSC aging were not observed in *Prx1-Cre;Bmi1*^*fl/fl*^ mice. For example, myeloid bias of HSCs after transplantation, a defining feature of HSC aging ([@bib15]), was not observed in HSCs isolated from *Bmi1*-deficient mice. Thus, while reduction in *Bmi1* expression during aging may contribute to the age-related expansion of adipocytes in the HSC niche, it is insufficient to cause a major aging phenotype in HSCs. Additionally, whether *Bmi1* reduction contributes to age-associated bone loss or BMSC loss remains unclear. Future investigation should shed light on additional age-associated changes in the niche, such as in the endothelial cells, as well as molecules produced by BMSCs that induce quiescence and aging of HSCs.

We found that deletion of *Bmi1* from BMSCs reduces not only the H2Aubi mark catalyzed by the PRC1 but also the H3K27me3 mark decorated by the PRC2. These findings are consistent with the recently proposed model describing that the PRC1-catalyzed H2Aubi can stabilize PRC2 and the H3K27me3 modification on chromatin ([@bib6], [@bib44]). Both H2Aubi and H3K27me3 were reduced on known polycomb target genes, such as the *Hox* and the *Ink4a/Arf* genes, causing derepression of these genes. We also identified *Pax3*, a master regulator of neural crest development ([@bib7]), as a potential target of BMI1/PRC1 whose promoter region is modified by H2Aubi and H3K27me2 in a *Bmi1*-dependent manner. *Pax3* has also been found to distinguish brown adipocytes from white adipocytes ([@bib17], [@bib31]), but whether *Pax3* regulates adipogenesis of bone marrow BMSCs is unknown. Further work should delineate the role of *Bmi1* and *Pax3* in regulating the bone marrow niche for HSCs and age-related increase in adipogenesis.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

C57BL/Ka-Thy-1.2 (CD45.1) mice (8--12 weeks of age) were used for HSC transplantation assays. *Bmi1*^*fl/fl*^ mice were described previously ([@bib30]). *Prx1-Cre* (JAX: 005584) and *Vav1-Cre* (JAX: 008610) mice were obtained from The Jackson Laboratory. Age- and sex-matched pairs were analyzed in each experiment otherwise specified in figure legends. Mice were housed in AAALAC-accredited, specific-pathogen-free animal care facilities at Baylor College of Medicine (BCM). All procedures were approved by BCM Institutional Animal Care and Use Committees.

Statistics {#sec4.2}
----------

Statistics were determined with a paired or unpaired Student\'s t test or ANOVA with Prism software (GraphPad). Group data represent mean ± standard deviation in all results. No randomization or blinding was used in any experiments. Experimental mice were not excluded from analysis in any experiments. Sample sizes were selected on the basis of previous experience with the degree of variance in each assay.

CFU-F Assays {#sec4.3}
------------

One million enzymatically digested bone marrow cells were cultured per well of a 6-well plate in α-minimal essential medium (α-MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 5% human platelet lysate (STEMCELL Technologies, Vancouver, Canada). After 10--14 days, the cultures were washed with PBS and stained with 1% crystal violet (C0775, Millipore Sigma, Burlington, MA) in methanol. Colonies with more than 50 cells were counted as a colony-forming unit. SAβ-gal staining was done with the Senescence β-Galactosidase Staining Kit (\#9860, Cell Signaling Technologies, Danvers, MA).

Body Composition and Adiponectin Level Measurements {#sec4.4}
---------------------------------------------------

Body composition of 6-month-old mice was assessed by magnetic resonance imaging and circulating adiponectin levels were measured by a Mouse Adiponectin ELISA kit (EZMADP-60K, Millipore) according to the manufacturer\'s instructions, both by the BCM Mouse Metabolic and Phenotyping Core.

BMSC Differentiation Assays {#sec4.5}
---------------------------

To induce osteogenic differentiation, we cultured BMSCs in α-MEM supplemented with 20% heat-inactivated FBS, 10 nM dexamethasone (D1759), 100 mM ascorbic acid (49752), and 10 mM β-glycerophosphate (G9422, all from Millipore Sigma). For evaluation of osteogenesis, cells were fixed in 4% paraformaldehyde (PFA), washed twice with PBS, and stained with 2% Alizarin red S solution (pH 4.3; A5533, Millipore Sigma). Adipogenic differentiation was induced with Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% heat-inactivated FBS, 0.5 mM indomethacin (I7378, Millipore Sigma), 1 μM dexamethasone, and 10 μg/mL insulin (91077C, Millipore Sigma). The differentiation medium was changed every 2--3 days. For evaluation of adipogenesis, cells were fixed in 4% PFA and stained with filtered oil red O solution for 15 min at 37°C. After washing with 60% isopropanol, cells were either imaged or oil red O extracted with 100% isopropanol and quantified by the absorption of 500 nm with a spectrophotometer. To induce chondrogenic differentiation, we cultured BMSCs in MSC chondrogenic differentiation medium (PT-3003, Lonza, Allendale, NJ) supplemented with 10 ng/mL TGFβ3 (PT-4124, Lonza) according to the manufacturer\'s instructions. For evaluation of chondrogenesis, cell aggregates were cryosectioned, fixed in 4% PFA, stained with toluidine blue O solution (pH 4.5), and imaged.

μCT Analysis {#sec4.6}
------------

Femurs were fixed in 4% PFA for 48 h at room temperature, washed in PBS, and stored in 70% ethanol before scanning. To quantify bone marrow adipocytes in the bone marrow, we fixed femurs in 10% formalin at 4°C overnight and washed them in running water. Bones were decalcified in 14% EDTA for approximately 14 days. Decalcified bones were stained in 1% osmium tetroxide with 2.5% potassium dichromate for 48 h at room temperature before washing and scanning. μCT scanning was performed with the following parameters: energy of 55 kV, a diameter of 16,384 μm, an intensity of 145 μA, and a maximum isometric voxel size of 16 μm using a Scanco Medical Micro-CT-40 (Scanco Medical, Bruttisellen, Switzerland) and μCT V6.1 software. μCT scanning for osmium-stained samples was done with the voxel size of 8 μm.

Lentiviral shRNA Transduction {#sec4.7}
-----------------------------

The pLKO shRNA plasmids were purchased from Sigma-Aldrich (St. Louis, MO). To generate lentiviral particles, we transiently transfected 293T cells with pLKO vectors with psPAX2 (12260) and pMD2.G (12259) from Addgene. Culture supernatant was collected after 48 h and used to transduce freshly isolated BMSCs for 48 h. After infection, medium was changed to α-MEM supplemented with 10% heat-inactivated FBS and 5% human platelet lysate.

HSC Transplantation {#sec4.8}
-------------------

Fifty HSCs were sorted from mice and transplanted along with 200,000 competitor whole bone marrow cells from CD45.2 mice into lethally irradiated (two doses of 500 cGy) CD45.1 mice. Recipient mice were bled monthly and mononuclear cells were analyzed by flow cytometry.

Quantitative Real-Time PCR {#sec4.9}
--------------------------

BMSCs, stroma cells, and hematopoietic cells were sorted into TRIzol (Thermo Fisher Scientific, Waltham, MA) and RNA was isolated according to the manufacturer\'s instructions. cDNA was made with random primers and SuperScript IV VILO reverse transcriptase (Thermo Fisher Scientific). qPCR was performed using a ViiA7 Real-Time PCR System (Thermo Fisher Scientific). Primers are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.
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